Case StudyDataNeuroSupporting payer adoption with real-world evidence: Nalu Medical demonstrates value with OM1 dataRead more
PublicationAINeuroCharacterizing Disease Progression in Multiple Sclerosis Subtypes Using RWD: Feasibility of Applying a Machine Learning Model to Address Missing DataDownload
PublicationDataNeuroAssessing the Expanded Disability Status Scale in Secondary Progressive Multiple Sclerosis Patients Treated with Disease Modifying Therapies within a Large, Representative Real World Multiple Sclerosis RegistryDownload
PublicationDataNeuroAssessing Comorbid Behavioral Health Conditions, Healthcare Resource Utilization, and Medication Use in Patients Seeking Mental Health Care within a Large, Representative Real-World Multiple Sclerosis RegistryDownload
PublicationDataNeuroComparison of Symptoms, Treatments, and Healthcare Resource Utilization in Patients with Multiple Sclerosis by Sex in a Real-World Cohort in the U.S.Download
PublicationDataNeuroA Real-World Retrospective Analysis of Outcomes in Multiple Sclerosis Patients Who Transitioned to Alemtuzumab After Rituximab or OcrelizumabDownload
PublicationDataNeuroTreatment Patterns and Reasons for Switching among U.S. Patients with Multiple Sclerosis Taking the Glatiramer Acetate Class of ProductsDownload
PublicationAINeuroPredicting Relapse Episodes in Patients with Multiple Sclerosis Treated with Disease Modifying Therapies in a Large Representative US-Based Real World CohortDownload
PublicationDataNeuroRevisiting MS Prevalence in the 21st Century: Exploration Based on a Large Representative US-Based Real-World CohortDownload
PublicationDataNeuroReal-World Switching Patterns Among US Generic Glatiramer Acetate Multiple Sclerosis PatientsDownload
PublicationDataNeuroDiagnosis of Frontotemporal Dementia is Often in Non-Specialist Settings and Complicated by Non-FTD Dementia and Psychiatric DiagnosesDownload
PublicationDataNeuroUsing Real-World Data and Digital Phenotyping to Identify Candidates for anti-CGRP Migraine TreatmentDownload
PublicationDataNeuroReal-world healthcare utilization and costs of peripheral nerve stimulation with a micro-IPG systemDownload
PublicationAINeuroValidation of a Machine Learning Approach to Estimate Expanded Disability Status Scale Scores for Multiple Sclerosis.Read more
News & ArticleDataNeuroOM1 expands neurology network to over 3 million patients for real-world data researchRead more
News & ArticleDataNeuroOM1 Adds a Half Million Patients to Neurology Network, Strengthening Real-World Evidence Generation and Accelerating Innovation in NeurologyRead more
News & ArticleDataNeuroNalu PNS System Significantly Reduces Healthcare-Related Costs in Chronic Pain PatientsRead more
News & ArticleDataAINeuroQ&A: New Alzheimer’s dataset allows ‘whispers from the brain’ to assist in early detectionRead more
News & ArticleAINeuroOM1 Contributes to Alzheimer’s Disease Research With New PremiOM Dataset of Over 1 Million PatientsRead more
News & ArticleAINeuroMachine Learning Model Enhances Real-World Studies for Predicting Disability Progression in Multiple SclerosisRead more
News & ArticleAINeuroDr Carl Marci talks real-world data, early detection of Parkinson’s and how personalized intervention is key to quality of life.Read more
PodcastAINeuroThe Sooner, the Better: Detecting and Decoding Alzheimer’s with Real-World DataRead more
News & ArticleDataNeuroOM1 Launches Parkinson’s Disease Premium Dataset to Expand Real-World Evidence in NeuroscienceRead more
News & ArticleAINeuroUsing Real-World Data for Patients with Multiple Sclerosis: A New Machine Learning Model for the Expanded Disability Status Scale (EDSS)Read more
News & ArticleAINeuroValidation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosisRead more
News & ArticleDataNeuroOM1 Launches Multiple Sclerosis Registry with More than 20,000 Patients Prospectively Followed with Deep Clinical DataRead more
![WEST PALM BEACH, Fla. — Application of a machine learning model to databases of patients with multiple sclerosis expanded understanding of disease progression, according to a poster at ACTRIMS 2024.“The [Expanded Disability Status Score] is a critical endpoint in clinical trials, but in the real world it’s not routinely collected,” Carl D. Marci, MD, managing director of](/_next/image/?url=https%3A%2F%2Fimages.ctfassets.net%2Fddhe5ahaolzf%2F4REDjTfHWo8BdGhY9fL7m0%2F5ea3f642f251fdeb7a094009955985dc%2Fmachine-learning-ai213593664.jpg&w=3840&q=75)
